Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) has scheduled its second quarter 2025 financial results release for Wednesday, August 6, 2025, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET (7:30 a.m. CT) on the same day.
Management will present the financial results and provide a business update during the call. Investors can access the live webcast through the Events page on Lexicon's investor relations website, and those wishing to ask questions can register to receive dial-in information.
Positive
- None.
Negative
- None.
THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
When will Lexicon Pharmaceuticals (LXRX) report Q2 2025 earnings?
What time is Lexicon's Q2 2025 earnings conference call?
How can investors access Lexicon Pharmaceuticals' Q2 2025 earnings call?
Will Lexicon's Q2 2025 earnings call be available for replay?
